MedTrace Logo

Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

NCT04393220 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-09-05

No results posted yet for this study

Summary

The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.

Conditions

  • Progress Free Survival (PFS) and Overall Survival (OS)

Interventions

DRUG

Bevacizumab Injection

15mg/kg (Q3W)

DRUG

Nivolumab

nivolumab 480 mg IV infusions for 30 minutes q4w

Sponsors & Collaborators

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2021-07-30
Completion
2021-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04393220 on ClinicalTrials.gov